Conor E. Steuer, MD, is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Steuer is a medical oncologist specializing in the care of aerodigestive cancers, mesothelioma and thymic malignancies. He joined the clinical staff at Winship Cancer Institute as a practicing physician in July 2015. Dr. Steuer received his medical degree from NYU School of Medicine. He completed his postdoctoral training as a Fellow in the Department of Hematology and Medical Oncology at Emory University School of Medicine where he was Chief Fellow in his final year. Research Dr. Steuer has been active in research including clinical trial development, database analyses, and investigation of molecular biomarkers. He is interested in investigating the molecular biology and genomics of thoracic and head and neck tumors in order to be able to further the care of these patient populations. Additionally, he has taken an interest in utilizing national databases to perform clinical outcomes research, as well as further investigate rare forms of thoracic cancers.

CSO and Thoracic Medical oncologist

Dr. Jonathan Spicer is an assistant professor of surgery at McGill University, where he is the medical director of the McGill University Health Center (MUHC) Thoracic Oncology Network. He chairs the McGill regional thoracic oncology tumor board and is co-director of the MUHC thoracic oncology clinical trials unit. Dr. Spicer is a surgeon scientist leading a broad research program covering basic, translational and clinical research topics. He trained in general surgery at McGill University and subsequently in cardiothoracic surgery at the University of Texas, MD Anderson Cancer Centre. On a basic science front, Dr. Spicer is recognized as a leader in our understanding of how neutrophils impact cancer progression, and in particular, on the role of neutrophil extracellular traps in cancer biology. On a clinical front, Dr. Spicer has developed one of the most active research programs in the area of neoadjuvant immunotherapy for operable lung cancer. He is an expert in surgical enhanced recovery protocols and his clinical practice is focused on minimal access techniques for pulmonary surgery and extended resections for thoracic malignancies. He is the program director for the McGill Advanced Thoracic and Upper GI Surgical Oncology Fellowship. Dr. Spicer is the research chair for the Canadian Association of Thoracic Surgeons, director of the Canadian Cancer Trials Mesothelioma Working Group and sits on numerous steering committees for phase 2 and 3 international trials investigating the use of novel therapies prior to lung cancer resections.

Dr Skoulidis obtained a Medical Degree from the Aristotle University of Thessaloniki, Greece in 2000 and a PhD from the University of Cambridge, UK in 2011. He completed general medicine residency and medical oncology fellowship training in Cambridge and London, UK before moving to the University of Texas MD Anderson Cancer Center in 2013, where he is currently a Tenure-Track Assistant Professor (Physician Scientist) in the Department of Thoracic/Head and Neck Medical Oncology. Dr Skoulidis’ laboratory is focused on (a) unraveling the molecular and clinical heterogeneity of KRAS-mutant non-small cell lung cancer (NSCLC) and developing novel therapeutic strategies to target KRAS-mutant lung tumors and (b) elucidating the impact of individual somatic genomic alterations on the NSCLC immune contexture and immunotherapy response, with the goal of developing novel precision oncogenotype-tailored immunotherapeutic strategies. Dr Skoulidis has received a number of awards for his research including a 2019 AACR NextGen Star award. His work has been published in high impact scientific journals including Cancer Discovery, Cancer Cell, Nature Reviews Cancer and his research has attracted research funding from the Cancer Prevention and Research Institute of Texas, the US Department of Defense and the NIH.

Dr. Harpreet Singh is the Director of the Division of Oncology 2 in the Office of Oncology Diseases, as well the Acting Associate Director for Cancer in Older Adults and Special Populations in the Oncology Center of Excellence at the US FDA. Dr. Singh received her M.D. degree from the University of Southern California. She completed her Internal Medicine residency and Geriatrics fellowship at USC, followed by a Medical Oncology fellowship at the National Cancer Institute. FDA Guidance of Industry on Inclusion of Older Adults in Cancer Clinical Trials. As Director of the Division of Oncology 2, Dr. Singh oversees drug development for lung cancer, head and neck cancer, neurologic tumors, pediatric solid tumors, and rare cancers. Her scope of expertise includes precision medicine and targeted therapy, novel trial design, innovative regulatory initiatives designed to expedite drug approvals, and use of real world data in regulatory decision making. Recent notable approvals in lung cancer include targeted therapies for MET exon 14 skipping mutations and RET fusions. In her role as AD for Cancer in Older Adults, Dr. Singh leads multiple OCE efforts to advance drug development and regulatory science for older adults with cancer and special populations. Dr. Singh has expertly engaged with the greater scientific community, to increase the evidence base for treating older adults with cancer. She has consistently presented her FDA research on this topic at major academic conferences, and published in peer reviewed journals such as the Journal of Clinical Oncology (JCO). Most recently, she spearheaded an She serves as the lead for OCE

Yu Shyr received his Ph.D. in biostatistics from the University of Michigan (Ann Arbor) in 1994 and subsequently joined the faculty at Vanderbilt University School of Medicine.  Dr. Shyr is a Fellow of the American Statistical Association (ASA), an elected fellow of the American Association for the Advancement of Science (AAAS) and a US Food and Drug Administration (FDA) advisory committee voting member. He has published more than 480 peer-reviewed papers in a variety of journals (h-index = 104).  Dr. Shyr was the member of the US National Academy of Medicine (IOM) Committee on Policy Issues in the Clinical Development of Biomarkers for Molecularly Targeted Therapies. He has served as a member of the US National Cancer Institute (NCI) Developmental Therapeutics Study Section, Cancer Immunopathology and Immunotherapy Study Section and the Population and Patient-oriented Training Study Section.  Dr. Shyr was the co-course director for the AACR/ASCO Methods in Clinical Cancer Research Vail Workshop. He is the Associate Editor for JAMA Oncology, and Journal of Thoracic Oncology (JTO). Dr. Shyr’s current research interests focus on developing statistical bioinformatic methods for analyzing next-generation sequencing data based on single cell technology and novel statistical methods for analyzing the ICI survival data.

Leo Shunyakov, MD, is hematology and oncology medical director at Central Care Cancer Center in Bolivar, Missouri. Dr Shunyakov earned his medical degree from the Urals Medical Academy in Yekaterinburg, Russia. He then completed a fellowship in hematology/oncology at University of Rochester, Rochester, NY. Dr Shunyakov is an active researcher with interests including hematology/oncology, biological cancer treatments, as well as chemotherapy and nonchemotherapy cancer treatments.

Dr. Elaine Shum is an Assistant Professor at NYU Langone Health’s Perlmutter Cancer Center. She received her medical degree from Stony Brook University School of Medicine and completed her hematology and oncology fellowship at Albert Einstein College of Medicine/Montefiore Medical Center. At Perlmutter Cancer Center, Dr. Shum treats patients with lung cancer and other thoracic malignancies and is an active member of the Phase I group. She serves as the principal investigator of several thoracic malignancy and Phase I clinical trials at NYU.

Assistant Professor of Medicine and Clinical Director, Thoracic Medical Oncology, Columbia University Medical Center

Frances A. Shepherd, OC, OOnt, MD, FRCPC, FASCO, LLD (Hon)

Dr. Shepherd received her medical degree from the University of Toronto, and currently is a Physician at Princess Margaret Cancer Centre, Toronto, where she holds the Scott Taylor Chair in Lung Cancer Research. She is a University Professor of Medicine at the University of Toronto. She chaired the Lung Cancer Committee of the National Cancer Institute of Canada Clinical Trials Group for 19 years and was IASLC President 2003-to 2005. She has been a member of the ASCO and EORTC Boards of Directors She received the Jacqueline Seroussi Award for Cancer Research (Israel, 2004); the NCI Canada Warwick Award for Research Excellence (2006); the IASLC Research Award (2007); the Ontario Premier’s Summit Research Award (2009); and a Boehringer-Ingelheim Innovation Award (2010). In 2012, she won the British Thoracic Oncology Group International Award, the Royal College of Physicians and Surgeons of Canada Whiteman Award, a Queen Elizabeth II Diamond Jubilee medal and Giants of Cancer Care Award. She received the Order of Ontario (2007); Officer of the Order of Canada (2017), and a Gairdner-Wightman award (2018). She has honourary doctorates from York University (2019) and Faculty of Medicine University of Ottawa (2019). Dr Shepherd’s clinical trials have changed treatment and outcomes for patients with lung cancer at a global level. She has mentored more than 45 post-doctoral research students from around the world, and authored or co-authored more than 550 publications and 35 book chapters.